



Resource impact statement

Resource impact

Published: 27 May 2025

www.nice.org.uk

The guideline update sets out recommendations on anti-D prophylaxis for people who are rhesus D negative and are having an abortion. The updated recommendations advise people to follow [World Health Organization \(WHO\) abortion care guidelines](#), which the Royal College of Obstetricians and Gynaecologists base their recommendations on.

The WHO recommendations advise against anti-D immunoglobulin administration for both medical and surgical abortion at less than 12 weeks. The previous NICE guideline recommended offering anti-D prophylaxis to people who are rhesus D negative and having an abortion after 10 weeks' gestation, and to consider anti-D prophylaxis for people who are having a surgical abortion up to and including 10 weeks' gestation. An existing recommendation was amended to ensure that people who need anti-D prophylaxis when having an abortion at 12 weeks or over do not incur delays in receiving treatment because of their rhesus status testing or the availability of anti-D prophylaxis.

For hospitals and clinics that currently follow the WHO guidelines, this update will not result in a change in practice.

For hospitals and clinics that currently follow the previous NICE guideline, savings will be generated as services will no longer need to test rhesus D status in people having an abortion at less than 12 weeks. Testing for rhesus D status is primarily undertaken by point-of-care tests in the independent sector, but hospitals will likely be using serum testing, which may require an additional appointment with a phlebotomist or nurse. Costs of the tests will vary depending on the test used and the amount of additional time needed to administer.

The resulting reduction in anti-D prophylaxis use may in turn lead to some further cost savings. Treatment with anti-D prophylaxis is inexpensive and the estimated population for those needing treatment in England is around 2,700, so any savings generated by not needing to offer anti-D prophylaxis are likely to be moderate.

In 2022, 99% of abortions in England and Wales were funded by the NHS, with 80% of abortions taking place in the independent sector (see the [Office for Health Improvement and Disparities' abortion statistics in England and Wales](#)). The potential savings will only be fully realised by the NHS if the abortion tariffs are reduced to reflect the changes.